(Giving) Back to school: Cardinal Health shows commitment to pharmacy education with additional $1 million scholarship fund
Pictured above: 2014 participants of the Cardinal Health Pharmacy Scholarship Program
LAS VEGAS — As part of its continued commitment to the practice of pharmacy and the future of the profession, Cardinal Health this year will award a total of more than $1 million to 10 pharmacy schools across the country through its Cardinal Health Pharmacy Scholarship Program.
“We understand the impact independent pharmacists have on their communities, and the significant role they play in providing cost-effective care that improves patients’ health,” said Jon Giacomin, CEO Cardinal Health's Pharmaceutical segment. “Supporting future community pharmacy leaders through this scholarship program is an honor, and we continue to be inspired by the next generation of innovative, patient-focused pharmacy owners as they begin serving their communities.”
In addition, all scholarship recipients receive an all-expenses-paid trip to attend a pharmacy ownership workshop at the University of South Carolina. Cardinal Health provides the funds to the schools, which, in turn, select the students. The scholarships are intended for fourth and fifth year pharmacy students who have demonstrated an interest in independent pharmacy through their coursework, extracurricular activities and residencies.
The schools selected to participate in the Cardinal Health Pharmacy Scholarship Program were chosen based on their commitment to advancing the independent pharmacy profession. All of the schools offer curricula focused on operating an independent pharmacy, support student-run chapters of the National Community Pharmacists Association, endorse internship and co-op programs with local independent retail pharmacies and demonstrate high post-graduate placement rates in community pharmacy settings.
This year’s winning Cardinal Health Pharmacy Scholarship Program schools include:
• Lipscomb University, Nashville
• North Dakota State University, Fargo, N.D.
• Ohio Northern University, Ada, Ohio
• Samford University, Birmingham, Ala.
• South Dakota State University, Brookings, S.D.
• University of Georgia, Athens, Ga.
• University of Montana, Missoula, Mont.
• Washington State University, Pullman, Wash.
• Western University of Health Sciences, Pomona, Calif.
• Wingate University, Wingate, N.C.
In the last four years, Cardinal Health has donated a total of more than $5 million to 28 universities through the program.
Drug Store News will be covering all the action at Cardinal Health RBC 2015 in a series of exclusive daily editions, in both print and digital formats. To keep up with all of the highlights, visit DrugStoreNews.com/Cardinal-Health-RBC or follow #RBCWin on Twitter.
ACPE accredits Western New England University College of Pharmacy
SPRINGFIELD, M.A. — The Accreditation Council for Pharmacy Education has fully accredited Western New England University College of Pharmacy.
“I am certain that the College of Pharmacy will be a nationally recognized leader in pharmacy education,” Western New England University President Anthony S. Caprio said. “The College of Pharmacy has developed an innovative curriculum under the remarkable leadership of Dean Evan Robinson, who has successfully recruited a highly talented faculty, to bring the College to this accreditation recognition.”
The college graduated its first class of Doctor of Pharmacy students in May.
“From the earliest stages of this endeavor everyone came together to develop the academic program literally from the ground up,” Evan Robinson, dean of the College of Pharmacy, said.
The first class of students consisted of about 75 students per year.
ACPE noted the strength of the college’s professional development sequence and the emphasis it places on professionalism.
The college is located within the 127,000-square-foot Center for the Sciences and Pharmacy, which opened in January 2011.
Sandoz launches generic Angiomax through Medicines Company partnership
PRINCETON, N.J. — Sandoz has launched its generic version of Angiomax (bivalirudin), an anticoagulant injection. The drug’s U.S. launch is the result of a supply and distribution agreement with the Medicines Company.
“This agreement with The Medicines Company for an authorized generic bivalirudin reflects our commitment to making high-quality generic injectables available to patients and healthcare professionals in the U.S.,” Sandoz President Peter Goldschmidt said.
Bivalirudin is an anticoagulant indicated for patients with unstable angina undergoing coronary angioplasty, as well as those undergoing percutaneous coronary intervention or those with heparin-induced thrombocytopenia, among other indications. IMS Health projected that in the 12 months ending in April 2015, the brand-name treatment sales were about $485 million.